Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on MetaVia. The associated price target remains the same with $8.00.

Introducing TipRanks MCP for Agents

• Deliver institutional-grade market data directly into Claude, ChatGPT, Cursor, and other MCP-compatible AI tools.
• Designed for personal research, portfolio monitoring, and AI-assisted investment workflows.

Jason McCarthy has given his Buy rating due to a combination of factors, centered on MetaVia’s advancing cardiometabolic pipeline and newly reported synergistic combination data. He highlights that vanoglipel, an oral GPR119 agonist, showed compelling preclinical synergy when paired with resmetirom and metformin in MASH and obesity models, driving marked weight and fat mass reductions despite neither partner drug being a stand‑alone weight loss agent.

He also points to MetaVia’s broader platform, including DA-1726, a dual GLP‑1/glucagon agonist with ongoing Phase 1 work and an important titration readout expected in 4Q26, as a differentiated approach to increasing energy expenditure while managing appetite. In his view, the strength of the combination data, the focus on high‑value metabolic indications, and the optionality created by oral vanoglipel as a partner to other agents support the current valuation and justify maintaining an $8 price target and a Buy rating on MTVA shares.

According to TipRanks, McCarthy is an analyst with an average return of -14.4% and a 28.40% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Plus Therapeutics, Medicus Pharma Ltd, and Atossa Therapeutics.

In another report released on June 9, H.C. Wainwright also maintained a Buy rating on the stock with a $20.00 price target.